Clinical trials: Cytoprotection
Covid19
COVID-19 Subcutaneously and Orally Administered Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
This is a phase 1/2 study in adult healthy subjects that have previously been vaccinated with an FDA-authorized vaccine against COVID-19.
- Trial name
- NCT04845191
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Traumatic Brain Injury
Efficacy of Ketamine in Children With Severe Brain Injury for Brain Cell Protection
The purpose of this study is to determine the possible effects of an anesthetic agent called Ketamine on the injured brain in children. The researchers think that it will effect the outcomes of children with these injuries.
- Trial name
- NCT00556387
- Testing
- saline, Ketamine
- Sponsor
- University of Arkansas
Mucositis, Multiple Myeloma
Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00482846
- Testing
- Palifermin, melphalan, questionnaire administration
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Covid19
COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines
This is a phase 1/2 study in adult healthy subjects that have previously been vaccinated with an FDA-authorized vaccine against COVID-19.
- Trial name
- NCT04843722
- Testing
- hAd5-S-Fusion+N-ETSD vaccine
- Volunteers
- healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Non-Erosive Gastro-Esophageal Reflux Disease, Gastroesophageal Reflux Disease (GERD)
Evaluation of the Clinical Course of NERD and Assessment of the Esophageal Mucosa Resistance
GERD is characterized by a high prevalence (about 13.3%) and is associated with a deterioration in the quality of life, as well as an increased risk of esophageal adenocarcinoma and a rise in the number of refractory cases.
- Trial name
- NCT07174882
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Acute Ischemic Stroke
Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke
Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders…
- Trial name
- TESSERACT 2 (NCT06440707)
- Testing
- High-definition Cathodal Transcranial Direct Current Stimulation (HD C-tDCS)
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of California, Los Angeles
Ischemic Stroke, Acute, Treatment Outcome
Effect of Early Versus Late Initiation of Edaravone Dexborneol on Neural Function in Patients With Acute Ischemic Stroke
The primary objective of this study was to evaluate the efficacy and safety of initiation of edaravone dextivel therapy compared with placebo in patients with acute ischaemic stroke (early and late) and to explore the optimal…
- Trial name
- EARLYS (NCT05885919)
- Testing
- Edaravone Dexborneol Concentrated Solution for injection
- Where
- 3 sites in China
- Volunteers
- 212 people
- Sponsor
- Xiangya Hospital of Central South University
Stroke Acute, Cytoprotection
Ischemic Postconditioning in Acute Stroke Patients Receiving Endovascular Thrombectomy
This clinical trial will evaluate whether on-site ischemic postconditioning (IPostC) improves outcomes in acute stroke patients receiving endovascular thrombectomy (EVT) and explore its mechanisms.
- Conditions
- Stroke Acute, Cytoprotection, Ischemic Conditioning
- Trial name
- NCT06967025
- Testing
- Ischemic Postconditioning, Endovascular Thrombectomy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Huanhu Hospital
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
High-Dose Chemotherapy and Autologous Blood Cell Transplantation in Treating Patients With Primary, Locally Advanced, or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003068
- Testing
- amifostine trihydrate, cyclophosphamide, mitoxantrone hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Bladder Cancer, Drug/Agent Toxicity by Tissue/Organ
Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00006105
- Testing
- amifostine trihydrate, cisplatin, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of Chicago
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Ischemia
Collection of Heart Tissue Sample During Open Heart Surgery
This study will collect heart tissue that is routinely removed and discarded during open-heart surgery. The Cardiology Branch of the NHLBI is conducting a variety of laboratory experiments that require a sample of heart tissue.
- Trial name
- NCT00423553
- Where
- United States
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Malignant Pleural Mesothelioma
Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
RATIONALE: After removal of visible cancer in the chest, chemotherapy drugs are used to kill or stop tumor cells from dividing, so that they stop growing or/and die.
- Trial name
- NCT00571298
- Testing
- Extrapleural pneumonectomy (EPP), Cisplatin, gemcitabine
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- Brigham and Women's Hospital
Myocardial Reperfusion Injury, Cytoprotection
The Protective Effects Of Treatment With Hyperbaric Oxygen Prior To Bypass Heart Surgery
The purpose of this study was to determine if treating patients who have coronary heart disease with hyperbaric oxygen (HBO) prior to coronary artery bypass graft (CABG) surgery reduces injury to the heart and vascular system…
- Trial name
- NCT00623142
- Testing
- Hyperbaric Oxygen
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- Hull University Teaching Hospitals NHS Trust